IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
April 21, 2020 07:30 ET | Idera Pharmaceuticals, Inc.
– Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 ...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Completes Enrollment in ILLUMINATE-301, its Registrational Trial of Tilsotolimod in Combination with Ipilimumab in Patients with Anti-PD-1 Refractory Advanced Melanoma
March 05, 2020 07:00 ET | Idera Pharmaceuticals, Inc.
EXTON, Pa., March 05, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or “the company”) (NASDAQ: IDRA) today announced completion of patient enrollment into ILLUMINATE-301, its...
Biotherapharma_logo.jpg
Biothera Pharmaceuticals to Present Immune Pharmacodynamic and Survival Data from Phase 2 Melanoma and Triple Negative Breast Cancer Study
November 05, 2019 10:00 ET | Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. will present two late-breaking posters highlighting immune pharmacodynamic data from its Phase 2 clinical study in...
Media Advisory - Save Your Skin Launches Inaugural “Move For Melanoma” Challenge Benefiting Skin Cancer Patients Across Canada
August 30, 2019 01:10 ET | Save Your Skin Foundation
VANCOUVER, British Columbia, Aug. 30, 2019 (GLOBE NEWSWIRE) -- On Friday, September 13th Save Your Skin Foundation will officially launch the 2019 Move for Melanoma Challenge. The unique campaign...
AB Science today reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma
August 02, 2019 11:44 ET | AB Science
Paris, August 2, 2019, 5.30pm AB Science announces new clinical results in oncology: Masitinib showed activity in metastatic melanoma bearingthe juxta-membrane mutation of c-Kit AB...
AB Science annonce aujourd’hui les résultats de son étude de phase 3 évaluant le masitinib chez des patients atteints de mélanome non opérable ou métastatique de stade 3 ou stade 4
August 02, 2019 11:44 ET | AB Science
Paris, 2 août 2019, 17h30 AB Science annonce de nouveaux résultats cliniques en oncologie :L’activité du masitinib a été démontrée dans le mélanome métastatiqueprésentant une mutation du domaine...
aad.jpg
Ahead of Memorial Day, the American Academy of Dermatology Reminds Americans to Use Protection
May 23, 2019 11:30 ET | American Academy of Dermatology
ROSEMONT, Ill., May 23, 2019 (GLOBE NEWSWIRE) -- An estimated 9,500 people in the United States are diagnosed with skin cancer every day, yet many Americans will put themselves at greater risk for...
aad.jpg
During Skin Cancer Awareness Month, Dermatologists Share 5 Common Sunscreen Mistakes — and How to Avoid Them; American Academy of Dermatology
May 14, 2019 14:30 ET | American Academy of Dermatology
ROSEMONT, Ill., May 14, 2019 (GLOBE NEWSWIRE) -- Skin cancer is the most common cancer in the United States, affecting one in five Americans in their lifetime. Yet according to dermatologists from...
aad.jpg
Dermatologists Say Sunscreen is a Vital Tool in the Fight Against Skin Cancer, the Most Common Cancer in the U.S.; American Academy of Dermatology
May 07, 2019 11:30 ET | American Academy of Dermatology
ROSEMONT, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Recent news about sunscreen has many consumers confused about the best approach for sun protection, and some have questioned whether they should be...
aad.jpg
“Do You Use Protection?” American Academy of Dermatology Study Finds Half of Americans Are Not Protecting Themselves Against Sun Damage
May 01, 2019 11:58 ET | American Academy of Dermatology
ROSEMONT, Ill., May 01, 2019 (GLOBE NEWSWIRE) -- Skin cancer is one of the most preventable types of cancer, yet new data shows Americans aren’t “practicing safe sun.” In a recent survey, the...